View by Specialty

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

Neuromuscular Disease News

SPONSORED CONTENT
Save
SPONSORED CONTENT
July 17, 2024
1 min read
Save

NYU Langone tops list again as best US hospital for neurology, neurosurgery

NYU Langone tops list again as best US hospital for neurology, neurosurgery

NYU Langone was again the top hospital in the United States for neurology and neurosurgery, according to the latest annual Best Hospitals Survey issued by U.S. News & World Report.

SPONSORED CONTENT
July 15, 2024
2 min read
Save

Prenatal air pollution exposure tied to increased risk for cerebral palsy

Prenatal air pollution exposure tied to increased risk for cerebral palsy

Prenatal exposure to ambient air pollution was associated with increased risk for children developing cerebral palsy, according to cohort study results published in JAMA Network Open.

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

SPONSORED CONTENT
July 09, 2024
1 min read
Save

Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s

Subcutaneous combination therapy improves ‘good on’ time in Parkinson’s

Treatment with an investigational subcutaneous combination therapy for Parkinson’s disease improved ‘good on’ time by almost 2 hours per day, was safe and efficacious with treatment effect similar across a range of subgroups.

SPONSORED CONTENT
July 05, 2024
2 min read
Save

Q&A: ‘Exciting time’ for research into, development of treatments for CIDP

Q&A: ‘Exciting time’ for research into, development of treatments for CIDP

Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.

SPONSORED CONTENT
July 02, 2024
1 min read
Save

PrimeC led to significant slowing in rate of decline in ALS at 12 months

PrimeC led to significant slowing in rate of decline in ALS at 12 months

NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.

SPONSORED CONTENT
July 01, 2024
3 min read
Save

Physical exercise prevents nerve damage caused by chemotherapy

Physical exercise prevents nerve damage caused by chemotherapy

Certain physical exercises may prevent nerve damage caused by chemotherapy among individuals being treated for cancer, results of a randomized study published in JAMA Internal Medicine showed.

SPONSORED CONTENT
June 28, 2024
1 min read
Save

Monoclonal antibody for FSHD improves muscle strength with no serious adverse events

Monoclonal antibody for FSHD improves muscle strength with no serious adverse events

Avidity Biosciences Inc. has announced positive data from the phase 1/2 FORTITUDE clinical trial of a proprietary monoclonal antibody that binds to the transferrin receptor 1 conjugated with a siRNA targeting DUX4 mRNA.

SPONSORED CONTENT
June 28, 2024
4 min watch
Save

VIDEO: Antibiotics linked to exacerbation of myasthenia gravis

VIDEO: Antibiotics linked to exacerbation of myasthenia gravis

DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of Neurology annual meeting.

SPONSORED CONTENT
June 27, 2024
1 min read
Save

Results positive in study of antisense oligonucleotide for Huntington’s disease

Results positive in study of antisense oligonucleotide for Huntington’s disease

Wave Life Sciences has announced positive results from its phase 1b/2a clinical trial of WVE-003, a potential disease-modifying therapeutic for Huntington’s disease.

SPONSORED CONTENT
June 25, 2024
1 min read
Save

FDA expands approval of Elevidys to children aged 4 years and older with DMD gene mutation

FDA expands approval of Elevidys to children aged 4 years and older with DMD gene mutation

The FDA has announced approval of a label expansion for Elevidys to include patients with Duchenne muscular dystrophy aged 4 years and older with a confirmed mutation in the DMD gene.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails